Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Rhythm Pharmaceuticals Inc 222 BERKELEY STREET 12TH FLOOR BOSTON MA 02116 USA

www.rhythmtx.com Employees: 226 P: 857-264-4280 F: 857-264-4299

Description:

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.

Key Statistics

Overview:

Market Capitalization, $K 4,030,350
Enterprise Value, $K 3,970,270
Shares Outstanding, K 61,457
Annual Sales, $ 77,430 K
Annual Net Income, $ -184,680 K
Last Quarter Sales, $ 33,250 K
Last Quarter Net Income, $ -43,640 K
EBIT, $ -265,530 K
EBITDA, $ -250,410 K
60-Month Beta 2.09
% of Insider Shareholders 5.60%
Float, K 58,015
% Float 94.40%
Short Volume Ratio 0.56

Growth:

1-Year Return 125.09%
3-Year Return 536.70%
5-Year Return 198.36%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -33.89%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.73 on 11/05/24
Next Earnings Date N/A
Earnings Per Share ttm -4.33
EPS Growth vs. Prev Qtr -32.73%
EPS Growth vs. Prev Year 3.95%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RYTM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -367.36%
Return-on-Assets % -77.47%
Profit Margin % -238.51%
Debt/Equity 0.00
Price/Sales 53.44
Price/Cash Flow N/A
Price/Book 368.95
Book Value/Share 2.50
Interest Coverage -12.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar